Further targeted systemic therapy is limited to non-resectable advanced stage patients with tumor genetic alterations such as ALK (anaplastic lymphoma kinase), MET (Met proto-oncogene), RET Ret proto-oncogene), and ROS1 (c-ROS proto-oncogene 1) [6,7,8,9,10,11,12,13,14,15]. This evidence concerns the gene MET and neoplasm.